NCT00179712 2016-12-01
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Celgene Corporation
Phase 1/2 Completed
Clinical Trials
3 trialsNCT01111903 2016-03-17
REV
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT00179725 2006-04-12
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Celgene
Phase 1/2 Terminated